IBDEI0H5 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7667,2)
 ;;=^5015492
 ;;^UTILITY(U,$J,358.3,7668,0)
 ;;=N00.2^^52^518^4
 ;;^UTILITY(U,$J,358.3,7668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7668,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,7668,1,4,0)
 ;;=4^N00.2
 ;;^UTILITY(U,$J,358.3,7668,2)
 ;;=^5015493
 ;;^UTILITY(U,$J,358.3,7669,0)
 ;;=N00.3^^52^518^5
 ;;^UTILITY(U,$J,358.3,7669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7669,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,7669,1,4,0)
 ;;=4^N00.3
 ;;^UTILITY(U,$J,358.3,7669,2)
 ;;=^5015494
 ;;^UTILITY(U,$J,358.3,7670,0)
 ;;=N00.4^^52^518^3
 ;;^UTILITY(U,$J,358.3,7670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7670,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,7670,1,4,0)
 ;;=4^N00.4
 ;;^UTILITY(U,$J,358.3,7670,2)
 ;;=^5015495
 ;;^UTILITY(U,$J,358.3,7671,0)
 ;;=N00.5^^52^518^6
 ;;^UTILITY(U,$J,358.3,7671,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7671,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,7671,1,4,0)
 ;;=4^N00.5
 ;;^UTILITY(U,$J,358.3,7671,2)
 ;;=^5015496
 ;;^UTILITY(U,$J,358.3,7672,0)
 ;;=N00.6^^52^518^1
 ;;^UTILITY(U,$J,358.3,7672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7672,1,3,0)
 ;;=3^Acute nephritic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,7672,1,4,0)
 ;;=4^N00.6
 ;;^UTILITY(U,$J,358.3,7672,2)
 ;;=^5015497
 ;;^UTILITY(U,$J,358.3,7673,0)
 ;;=N00.7^^52^518^2
 ;;^UTILITY(U,$J,358.3,7673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7673,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,7673,1,4,0)
 ;;=4^N00.7
 ;;^UTILITY(U,$J,358.3,7673,2)
 ;;=^5015498
 ;;^UTILITY(U,$J,358.3,7674,0)
 ;;=N00.8^^52^518^9
 ;;^UTILITY(U,$J,358.3,7674,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7674,1,3,0)
 ;;=3^Acute nephritic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,7674,1,4,0)
 ;;=4^N00.8
 ;;^UTILITY(U,$J,358.3,7674,2)
 ;;=^5015499
 ;;^UTILITY(U,$J,358.3,7675,0)
 ;;=N00.9^^52^518^10
 ;;^UTILITY(U,$J,358.3,7675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7675,1,3,0)
 ;;=3^Acute nephritic syndrome w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,7675,1,4,0)
 ;;=4^N00.9
 ;;^UTILITY(U,$J,358.3,7675,2)
 ;;=^5015500
 ;;^UTILITY(U,$J,358.3,7676,0)
 ;;=N01.0^^52^518^70
 ;;^UTILITY(U,$J,358.3,7676,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7676,1,3,0)
 ;;=3^Rapidly progr neph synd w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,7676,1,4,0)
 ;;=4^N01.0
 ;;^UTILITY(U,$J,358.3,7676,2)
 ;;=^5015501
 ;;^UTILITY(U,$J,358.3,7677,0)
 ;;=N01.1^^52^518^69
 ;;^UTILITY(U,$J,358.3,7677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7677,1,3,0)
 ;;=3^Rapidly progr neph synd w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,7677,1,4,0)
 ;;=4^N01.1
 ;;^UTILITY(U,$J,358.3,7677,2)
 ;;=^5015502
 ;;^UTILITY(U,$J,358.3,7678,0)
 ;;=N01.2^^52^518^67
 ;;^UTILITY(U,$J,358.3,7678,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7678,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,7678,1,4,0)
 ;;=4^N01.2
 ;;^UTILITY(U,$J,358.3,7678,2)
 ;;=^5015503
 ;;^UTILITY(U,$J,358.3,7679,0)
 ;;=N01.3^^52^518^65
 ;;^UTILITY(U,$J,358.3,7679,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7679,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,7679,1,4,0)
 ;;=4^N01.3
 ;;^UTILITY(U,$J,358.3,7679,2)
 ;;=^5015504
 ;;^UTILITY(U,$J,358.3,7680,0)
 ;;=N01.4^^52^518^64
